List of Finacea drug patents

Finacea is owned by Leo Pharma As.

Finacea contains Azelaic Acid.

Finacea has a total of 8 drug patents out of which 0 drug patents have expired.

Finacea was authorised for market use on 29 July, 2015.

Finacea is available in aerosol, foam;topical dosage forms.

Finacea can be used as topical treatment of inflammatory papules and pustules of mild to moderate rosacea.

The generics of Finacea are possible to be released after 28 February, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900554 LEO PHARMA AS Foamable composition and uses thereof
Oct, 2023

(8 months from now)

US10322085 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Oct, 2023

(8 months from now)

US8722021 LEO PHARMA AS Foamable carriers
Oct, 2023

(8 months from now)

US8435498 LEO PHARMA AS Penetrating pharmaceutical foam
Mar, 2024

(1 year, 1 month from now)

US7700076 LEO PHARMA AS Penetrating pharmaceutical foam
Sep, 2027

(4 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier
Oct, 2027

(4 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
Dec, 2027

(4 years from now)

US9211259 LEO PHARMA AS Antibiotic kit and composition and uses thereof
Feb, 2029

(6 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Market Authorisation Date: 29 July, 2015

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of FINACEA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in